A LIQUID CHROMATOGRAPHIC METHOD FOR THE RELIABLE QUANTIFICATION OF UPADACITINIB AND ITS SPECIFIED IMPURITIES
DOI:
https://doi.org/10.22159/ijap.2025v17i4.54010Keywords:
Upadacitinib, Impurities, UPLC, Empower software and PDA detectorAbstract
Objective: In the proposed investigation, a novel RP-UPLC technique for the simultaneous measurement of Upadacitinib and its impurities is developed. The technique's suitability for both tablet and bulk medication dose forms was confirmed.
Methods: A mobile phase consisting of 2.5 g of sodim hexane-1-sulphonic acid in 1 L of water was used to achieve an isocratic elution. The pH was adjusted to 3.0 using diluted formic acid: methanol (60:40) at a flow rate of 1 ml. min-1, using an X-Bridge Phenyl (250 x 4.6 mm, 5 µm) column.
Results: Sharp peaks of Upadacitinib and its impurities were detected at 6.730, 2.823, 3.844, 4.872, 9.991, 10.499, and 10.932 min, respectively, at 256 nm as the peak using the PDA detector. Among other aspects of system suitability, USP resolution is greater than or equal to 2, USP plate count exceeds 4000, and USP tailing is good. Purity Flag "No" means that the peak is uniform (provided by Empower program). If the purity angle is smaller than the purity threshold, the peak is homogeneous. The procedure was verified in accordance with the ICH recommendations. The procedure was validated in accordance with ICH recommendations. The concentration ranges of Upadacitinib (75–450 µg/ml), impurities 1, 2, 4, and 5 (2.50–15.00 µg/ml), and impurities 3 and 6 (1.25–7.50 µg/ml) were all subjected to linear regression for the calibration curve. LOQ (34.41, 0.057, 0.211, 0.181, 0.151, 0.377, and 0.165 µg ml–1) and LOD (11.35, 0.019, 0.070, 0.060, 0.049, 0.124, and 0.055 µg ml–1) for and Upadacitinib and impurities, respectively. Accuracy, precision, and resilience were among the other confirmed characteristics that were within acceptable ranges.
Conclusion: As a result, this method was chosen for shared analysis. Finally, the restrictions of the system-appropriate parameters and validation parameters are acceptable. Stability-indicating experiments under various stress conditions were successfully included to the approach.
References
Rinvoq Upadacitinib Tablet Extended Release. Daily Med; 2020 Mar 1.
Rinvoq EPAR. European Medicines Agency (EMA); 2019 Oct 16.
Drug Trials Snapshots: Rinvoq. US Food and Drug Administration (FDA); 2019 Aug 16.
Drug Approval Package: Rinvoq. US Food and Drug Administration (FDA); 2019 Sep 12.
AbbVie Receives FDA Approval of Rinvoq (upadacitinib) an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis. AbbVie. 2019 Aug 19.
Rinvoq: EPAR–public assessment report (PDF). European Medicines Agency; 2020 Mar 5.
Rinvoq 15 MG Retardtabletten. Austria codex (in German). Vienna: Osterreichischer Apothekerverlag; 2020.
Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 Aug 28;2:23. doi: 10.1186/s41927-018-0031-x, PMID 30886973.
Mohamed MF, Trueman S, Othman AA, Han JH, Ju TR, Marroum P. Development of in vitro in vivo correlation for upadacitinib extended-release tablet formulation. AAPS J. 2019;21(6):108. doi: 10.1208/s12248-019-0378-y, PMID 31654328.
Wang MJ, Zhao YH, Fan C, Wang YJ, Wang XQ, Qiu XJ. Development of an UPLC-MS/MS method for the quantitative analysis of upadacitinib in beagle dog plasma and pharmacokinetics study. Drug Des Dev Ther. 2021 Oct 2;15:4167-75. doi: 10.2147/DDDT.S332282, PMID 34629864.
Baje Syed I, Nannapaneni M. Related substances method development and validation of axitinib zanubrutinib and upadacitinib using RP-HPLC and its degradation products were characterized by using LC-MS/MS. Int J Pharm Investigation. 2022;13(1):113-21. doi: 10.5530/223097131696.
Li J, Chen C, Wang J, Ye Z, Pan L, Liu Z. Simultaneous measurement of upadacitinib and methotrexate by UPLC-MS/MS and its pharmacokinetic application in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Jan 1;1188:123071. doi: 10.1016/j.jchromb.2021.123071, PMID 34875493.
International conferences of harmonization validation of analytical procedures test and methodology. Validation of Analytical Procedures: Text and Methodology. 2005;Q2:R1.
Corradini DE, Eksteen E, Roy P. Schoenmakers and miller N. Handbook of HPLC. Chromatogr Sci S. 1998;78:907-21.
Christian GD. Analytical chemistry. 5th ed. New York: John Wiley & Sons; 1994. p. 385-6.
Kromidas S, Kuss HJ. Quantification in LC and GC: a practical guide to good chromatographic data. Weinheim: Wiley-VCH Press; 2009.
Andrews RW, Richardson H. Effect of spectral resolution detector linearity and chromatographic resolution on peak purity calculations. J Chromatogr A. 1994;683(1):3-8. doi: 10.1016/S0021-9673(94)89096-X.
Sethi PD. HPLC quantitative analysis of pharmaceutical formulations. India: CBS Publications; 2001.
Kishore VN, Ramana GV, Nadh RV, Gorumutchu GP. Simultaneous quantification of tiagabine and its related substance by a stability-indicating RP-HPLC method. Rasayan J Chem. 2021;14(4):2236-45. doi: 10.31788/RJC.2021.1446412.
Gorumutchu GP, Ratnakaram VN. Determination of mianserin using tropolone-OOO by ion pair formation. Int J Appl Pharm. 2019;11(1):168-73. doi: 10.22159/ijap.2019v11i1.30125.
Giri Prasad Gorumutchu, Venkata Nadh Ratnakaram, Kishore VNV. Ulipristal acetate determination using MBTH. Int J Res Pharm Sci. 2019;10(4):3369-75. doi: 10.26452/ijrps.v10i4.1646.
Gorumutchu GP, Ratnakaram VN. Determination of mianserine using Fe 3+ -phenanthroline by visible spectrophotometry. Res J Pharm Technol. 2019;12(1):209-12. doi: 10.5958/0974-360X.2019.00038.6.
Prasad GG, Nadh RV, Kiran KK. Ion associative complex formation for estimation of piperacillin. Int J Pharm Sci Res. 2019;10(1):117-24. doi: 10.26452/ijrps. v10i1.1787.
Gorumutchu GP, Ratnakaram VN, Malladi S. Ion pair formation for the determination of mianserin using fast sulphon black F. Asian J Pharm. 2018;12(4):S822-8. doi: 10.22377/ijgp.v12i04.2261.
Gorumutchu GP, Ratnakaram VN. Diazo coupling for the determination of selexipag by visible spectrophotometry. Int J Green Pharm. 2018;12(4):822-8. doi: 10.22377/ijgp.v12i04.2261.
Gorumutchu GP, Ratnakaram VN. Extractive spectrophotometric determination of ulipristal acetate using naphthol blue black. Res J Pharm Technol. 2019;12(3):1347-52. doi: 10.5958/0974-360X.2019.00226.9.
Kantheti S, Raju RR. A stability accuracy and robustness representing liquid chromatographic method for the quantification of zanubrutinib and its specified impurities. Int J App Pharm. 2023;15(5):210-20. doi: 10.22159/ijap.2023v15i5.48213.
Shyamal SA, Anitha P. Validated stability indicating RPHPLC method for determination of asenapine. Indo Am J Pharm Sci. 2018;5(5):4107-13.
Kalpana GL, Devalarao G, Raju MB, Kumar TP. Validated stability-indicating high-performance liquid chromatographic method for the quantification of asenapine. Int J Pharm Pharm Sci. 2015;7:61-5.
Published
How to Cite
Issue
Section
Copyright (c) 2025 SUBHASHINI KANTHETI, RUDRARAJU RAMESH RAJU, GIRI PRASAD GORUMUTCHU
This work is licensed under a Creative Commons Attribution 4.0 International License.
